20/20 바이오랩스AIDX 주가

20/20 Biolabs' OneTest Multi-Cancer Early Detection Blood Test Selected As Part Of Firefighter Cancer Screening Initiative For State Of Vermont In Partnership With National Diagnostic Services

Comprehensive Cancer Screening Initiative Expected to Generate Approximately $500,000 in Testing Revenues to 20/20 from the First CohortGAITHERSBURG, Md., May 27, 2026 (GLOBE NEWSWIRE) -- 20/20 Biolabs, Inc.

♻️ 재탕[8-K] 중대 사건 — CURRENT REPORT

♻️ 재탕[424B3] 424B3 — PROSPECTUS SUPPLEMENT

[424B3] 424B3 — PROSPECTUS SUPPLEMENT

20/20 Biolabs Q1 EPS $(0.28) Misses $(0.10) Estimate, Sales $353.375K Miss $779.000K Estimate

20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.10) by 180 percent. This is a 75 percent decrease over losses of $(0.16) per share from the

[8-K] 중대 사건 — CURRENT REPORT

[10-Q] 분기 실적 — QUARTERLY REPORT

12 Health Care Stocks Moving In Friday's After-Market Session

[NT 10-Q] 10-Q 제출 연기 — NOTIFICATION OF LATE FILING

20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026

GAITHERSBURG, Md., May 14, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (“20/20”) (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that management will attend the upcoming Sidoti Micro-Cap Virtual Conference. 20/20 BioLabs’ Chief Executive Officer, Jonathan Cohen, will participate in one-on-one investor meetings and host a presentation from 3:15 PM ET to 3:45 PM